View Financial HealthOctober PharmaE 배당 및 자사주 매입배당 기준 점검 0/6October PharmaE 은(는) 현재 수익률이 0.73% 인 배당금 지급 회사입니다.핵심 정보0.7%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.모든 업데이트 보기Recent updatesNew Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (ج.م4.32b market cap, or US$82.7m).Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). MD & Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Apr 06October Pharma S.A.E, Annual General Meeting, Apr 27, 2026October Pharma S.A.E, Annual General Meeting, Apr 27, 2026, at 15:30 Egypt Standard Time. Location: cairo EgyptBoard Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • May 13October Pharma S.A.E, Annual General Meeting, May 31, 2025October Pharma S.A.E, Annual General Meeting, May 31, 2025, at 12:00 Egypt Standard Time. Location: cairo EgyptReported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م2.67 (vs ج.م4.09 in 3Q 2023)Third quarter 2024 results: EPS: ج.م2.67 (down from ج.م4.09 in 3Q 2023). Revenue: ج.م326.1m (up 24% from 3Q 2023). Net income: ج.م32.0m (down 35% from 3Q 2023). Profit margin: 9.8% (down from 19% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Sep 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (9.9% net profit margin). Market cap is less than US$100m (ج.م1.41b market cap, or US$29.1m).Valuation Update With 7 Day Price Move • Sep 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م117, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 124% over the past three years.Reported Earnings • May 30First quarter 2024 earnings released: EPS: ج.م3.52 (vs ج.م2.94 in 1Q 2023)First quarter 2024 results: EPS: ج.م3.52 (up from ج.م2.94 in 1Q 2023). Revenue: ج.م274.4m (up 29% from 1Q 2023). Net income: ج.م50.1m (up 42% from 1Q 2023). Profit margin: 18% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.Reported Earnings • Mar 16Full year 2023 earnings released: EPS: ج.م12.53 (vs ج.م9.48 in FY 2022)Full year 2023 results: EPS: ج.م12.53 (up from ج.م9.48 in FY 2022). Revenue: ج.م1.01b (up 39% from FY 2022). Net income: ج.م182.1m (up 39% from FY 2022). Profit margin: 18% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Oct 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م1.20b market cap, or US$38.8m).Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to ج.م95.30, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 210% over the past three years.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).Reported Earnings • Jun 19First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ج.م165.8m (up 38% from 1Q 2020). Net income: ج.م40.6m (up 402% from 1Q 2020). Profit margin: 25% (up from 6.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: OCPH EG 시장에서 주목할만한 배당금을 지급하지 않으므로 지급이 안정적인지 확인할 필요가 없습니다.배당금 증가: OCPH EG 시장에서 주목할만한 배당금을 지급하지 않으므로 지급액이 증가하는지 확인할 필요가 없습니다.배당 수익률 vs 시장October PharmaE 배당 수익률 vs 시장OCPH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (OCPH)0.7%시장 하위 25% (EG)1.3%시장 상위 25% (EG)6.1%업계 평균 (Pharmaceuticals)2.2%분석가 예측 (OCPH) (최대 3년)n/a주목할만한 배당금: OCPH 의 배당금( 0.73% )은 EG 시장에서 배당금 지급자의 하위 25%( 1.31% )와 비교해 주목할 만하지 않습니다.고배당: OCPH 의 배당금( 0.73% )은 EG 시장에서 배당금 지급자의 상위 25%( 6.15% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 OCPH 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: OCPH EG 시장에서 주목할만한 배당금을 지급하지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YEG 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/16 22:44종가2026/06/16 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스October Pharma S.A.E는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.
Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).
Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (ج.م4.32b market cap, or US$82.7m).
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). MD & Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Apr 06October Pharma S.A.E, Annual General Meeting, Apr 27, 2026October Pharma S.A.E, Annual General Meeting, Apr 27, 2026, at 15:30 Egypt Standard Time. Location: cairo Egypt
Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • May 13October Pharma S.A.E, Annual General Meeting, May 31, 2025October Pharma S.A.E, Annual General Meeting, May 31, 2025, at 12:00 Egypt Standard Time. Location: cairo Egypt
Reported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م2.67 (vs ج.م4.09 in 3Q 2023)Third quarter 2024 results: EPS: ج.م2.67 (down from ج.م4.09 in 3Q 2023). Revenue: ج.م326.1m (up 24% from 3Q 2023). Net income: ج.م32.0m (down 35% from 3Q 2023). Profit margin: 9.8% (down from 19% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Sep 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 2.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (9.9% net profit margin). Market cap is less than US$100m (ج.م1.41b market cap, or US$29.1m).
Valuation Update With 7 Day Price Move • Sep 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م117, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 124% over the past three years.
Reported Earnings • May 30First quarter 2024 earnings released: EPS: ج.م3.52 (vs ج.م2.94 in 1Q 2023)First quarter 2024 results: EPS: ج.م3.52 (up from ج.م2.94 in 1Q 2023). Revenue: ج.م274.4m (up 29% from 1Q 2023). Net income: ج.م50.1m (up 42% from 1Q 2023). Profit margin: 18% (up from 17% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • May 21Upcoming dividend of ج.م2.50 per shareEligible shareholders must have bought the stock before 28 May 2024. Payment date: 30 May 2024. The company last paid an ordinary dividend in April 2017. The average dividend yield among industry peers is 3.3%.
Reported Earnings • Mar 16Full year 2023 earnings released: EPS: ج.م12.53 (vs ج.م9.48 in FY 2022)Full year 2023 results: EPS: ج.م12.53 (up from ج.م9.48 in FY 2022). Revenue: ج.م1.01b (up 39% from FY 2022). Net income: ج.م182.1m (up 39% from FY 2022). Profit margin: 18% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Oct 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م1.20b market cap, or US$38.8m).
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to ج.م95.30, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 210% over the past three years.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 9 non-independent directors. Director Hesham Abdul Soliman was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Apr 13Upcoming dividend of ج.م4.00 per shareEligible shareholders must have bought the stock before 20 April 2022. Payment date: 26 April 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.0%).
Reported Earnings • Jun 19First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ج.م165.8m (up 38% from 1Q 2020). Net income: ج.م40.6m (up 402% from 1Q 2020). Profit margin: 25% (up from 6.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Jun 02Inaugural dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 09 June 2021. Payment date: 13 June 2021. The company last paid an ordinary dividend in May 2018. The average dividend yield among industry peers is 4.2%.